Bristol-Myers Squibb BMY Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Revenues by Product | ||||||
| Abraxane | $50M-52.4% | $84M-51.7% | $74M-70.8% | $105M-54.5% | $105M-51.6% | |
| Breyanzi | $411M+56.3% | $392M+49.0% | $359M+60.3% | $344M+125% | $263M+146% | |
| Camzyos | $314M+97.5% | $354M+58.7% | $296M+89.7% | $260M+87.1% | $159M+89.3% | |
| Cobenfy | $56M+107% | $50M+400% | $43M— | $35M— | $27M— | |
| Eliquis | $4.14B+16.0% | $3.45B+8.0% | $3.75B+24.8% | $3.68B+7.7% | $3.57B-4.2% | |
| Krazati | $50M+4.2% | $56M+43.6% | $53M+55.9% | $48M+50.0% | $48M+129% | |
| Opdivo Qvantig | $163M+1,711% | $133M— | $67M— | $30M— | $9M— | |
| Opdivo | $2.15B-5.3% | $2.69B+8.6% | $2.53B+7.3% | $2.56B+7.2% | $2.27B+9.0% | |
| Opdualag | $295M+17.1% | $350M+37.8% | $299M+28.3% | $284M+20.9% | $252M+22.3% | |
| Orencia | $818M+6.2% | $1.01B+0.8% | $964M+3.0% | $963M+1.6% | $770M-3.5% | |
| Other Growth products | $581M+14.6% | $536M+1.7% | $514M+16.0% | $470M+35.1% | $507M+56.0% | |
| Other Legacy products | $156M-21.6% | $199M-20.4% | $177M-21.3% | $223M+0.5% | $199M-12.7% | |
| Other revenue | -$15M— | —— | —— | —— | $0— | |
| Pomalyst/Imnovid | $513M-22.0% | $692M-15.9% | $675M-24.8% | $708M-26.2% | $658M-23.9% | |
| Reblozyl | $555M+16.1% | $666M+21.8% | $615M+37.6% | $568M+33.6% | $478M+35.0% | |
| Revlimid | $349M-62.7% | $602M-55.0% | $575M-59.3% | $838M-38.1% | $936M-43.9% | |
| Sotyktu | $69M+25.5% | $85M+2.4% | $80M+21.2% | $70M+32.1% | $55M+25.0% | |
| Sprycel | $73M-58.3% | $80M-59.6% | $119M-59.0% | $120M-71.7% | $175M-53.2% | |
| Yervoy | $651M+4.3% | $810M+20.0% | $739M+15.1% | $728M+15.6% | $624M+7.0% | |
| Zeposia | $118M+10.3% | $159M+0.6% | $161M+9.5% | $150M-0.7% | $107M-2.7% | |
| Total Revenues by Geography | ||||||
| International | $3.44B+10.7% | $3.64B+7.0% | $3.6B+6.3% | $3.48B+8.0% | $3.11B-2.5% | |
| Other | $257M+17.9% | $309M-11.7% | $290M+7.0% | $270M+53.4% | $218M+9.5% | |
| United States | $7.79B-1.1% | $8.56B-0.4% | $8.33B+1.2% | $8.52B-3.2% | $7.87B-7.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Bristol-Myers Squibb break its business down?
- Bristol-Myers Squibb (BMY) reports total revenues by product across 20 parts — Abraxane, Breyanzi, Camzyos, Cobenfy and Eliquis. Each is extracted from the segment footnotes and tracked over time.
- Where does Bristol-Myers Squibb's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bristol-Myers Squibb's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
